West Pharmaceutical(US:WST) Financial Modeling Prep·2025-10-23 21:12Core Insights - West Pharmaceutical Services, Inc. has been upgraded to "Outperform" by Evercore ISI, with a price target increase from $350 to $390, while trading at $309.35 [1][6] Financial Performance - The company reported adjusted earnings per share (EPS) of $1.96 for Q3 2025, exceeding analyst expectations of $1.68, resulting in an earnings surprise of +17.37% [2][6] - Net sales reached $804.6 million, a 7.7% increase from the previous year, surpassing the expected $787.93 million [2] Segment Performance - Sales of Proprietary Products increased to $647.5 million, reflecting a 7.7% rise, with a 5.1% increase on an organic basis [3] - Contract-Manufactured Products saw sales of $157.1 million, up 8.0% overall and 4.9% on an organic basis [3] - The HVP Components business experienced double-digit growth, driven by demand for GLP-1 products and increased HVP conversion [3] Market Outlook - The company's annual profit forecast has been revised upwards due to strong demand for components essential for GLP-1 weight-loss and diabetes drugs [4][6] Stock Performance - WST's stock price is currently at $308.33, reflecting an 11.31% increase, with fluctuations between a low of $300 and a high of $322.34 during the day [5] - Over the past year, the stock reached a high of $352.33 and a low of $187.43, with a market capitalization of approximately $22.17 billion [5]